Metabolic Pathways of Leishmania Parasite: Source of Pertinent Drug Targets and Potent Drug Candidates
Open Access
- 30 July 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (8) , 1590
Abstract
Leishmaniasis is a tropical disease caused by a protozoan parasite Leishmania that is transmitted via infected female sandflies. At present, leishmaniasis treatment mainly counts on chemotherapy. The currently available drugs against leishmaniasis are costly, toxic, with multiple side effects, and limitations in the administration route. The rapid emergence of drug resistance has severely reduced the potency of anti-leishmanial drugs. As a result, there is a pressing need for the development of novel anti-leishmanial drugs with high potency, low cost, acceptable toxicity, and good pharmacokinetics features. Due to the availability of preclinical data, drug repurposing is a valuable approach for speeding up the development of effective anti-leishmanial through pointing to new drug targets in less time, having low costs and risk. Metabolic pathways of this parasite play a crucial role in the growth and proliferation of Leishmania species during the various stages of their life cycle. Based on available genomics/proteomics information, known pathways-based (sterol biosynthetic pathway, purine salvage pathway, glycolysis, GPI biosynthesis, hypusine, polyamine biosynthesis) Leishmania-specific proteins could be targeted with known drugs that were used in other diseases, resulting in finding new promising anti-leishmanial therapeutics. The present review discusses various metabolic pathways of the Leishmania parasite and some drug candidates targeting these pathways effectively that could be potent drugs against leishmaniasis in the future.Keywords
All Related Versions
This publication has 158 references indexed in Scilit:
- Identification and Functional Analysis of Trypanosoma cruzi Genes That Encode Proteins of the Glycosylphosphatidylinositol Biosynthetic PathwayPLOS Neglected Tropical Diseases, 2013
- Allosteric Activation of Trypanosomatid Deoxyhypusine Synthase by a Catalytically Dead ParalogJournal of Biological Chemistry, 2013
- Leishmania donovani Triose Phosphate Isomerase: A Potential Vaccine Target against Visceral LeishmaniasisPLOS ONE, 2012
- Leishmania Metacyclogenesis Is Promoted in the Absence of PurinesPLOS Neglected Tropical Diseases, 2012
- A Unique Modification of the Eukaryotic Initiation Factor 5A Shows the Presence of the Complete Hypusine Pathway in Leishmania donovaniPLOS ONE, 2012
- Axenic Leishmania amazonensis Promastigotes Sense both the External and Internal Arginine Pool Distinctly Regulating the Two Transporter-Coding GenesPLOS ONE, 2011
- Role of Heme and Heme-Proteins in Trypanosomatid Essential Metabolic PathwaysEnzyme Research, 2011
- Spiroindolones, a Potent Compound Class for the Treatment of MalariaScience, 2010
- Drug targets in LeishmaniaJournal of Parasitic Diseases, 2010
- Amiodarone and Miltefosine Act Synergistically against Leishmania mexicana and Can Induce Parasitological Cure in a Murine Model of Cutaneous LeishmaniasisAntimicrobial Agents and Chemotherapy, 2009